Challenges in developing immunotherapies for CLL compared to other hematologic malignancies

Challenges with immunotherapy in AML: on-target, off-tumor toxicityПодробнее

Key challenges in immunotherapy for AMLПодробнее

Advancing cellular therapies for blood cancersПодробнее

Key challenges in developing CAR-T therapy for CLLПодробнее

Engineering T cells: moving beyond leukemiaПодробнее

The challenges of implementing CAR-T therapy in CLLПодробнее

Challenges with implementing CARs in CLL and the promise of allogeneic productsПодробнее

Dr. Skarbnik on Combination Strategies of Immunotherapy in Hematologic MalignanciesПодробнее

Challenges with immunotherapy in ALLПодробнее

Challenges with immunotherapy in AML: target antigen selection, T-cell exhaustion and moreПодробнее

Challenges in developing CAR-T therapy for AMLПодробнее

Dr. Mato on Immunotherapy Options in CLLПодробнее

What You Need to Know About Developing CLL ResearchПодробнее

Chronic Lymphocytic Leukemia & Non-Hodgkin Lymphoma; Should all HL patients be treated the same?Подробнее

Challenges with CAR-T therapy in AML & insights into IF-BETTER-gated CAR-T cellsПодробнее

The challenges of choosing the right target antigen in AML compared to ALLПодробнее

Challenges of selecting frontline therapy in CLLПодробнее

Addressing issues with T-cell therapies for hematologic malignanciesПодробнее

Immunomodulation of NK cells for the treatment of lymphoid malignanciesПодробнее

Current challenges in CLL treatmentПодробнее